

PROVINCIAL FUNDING SUMMARY

Lutetium Lu 177 dotatate (Lutathera) for Gastroenteropancreatic neuroendocrine tumors (pCODR 10142)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: August 19, 2019

This information is current as of September 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration		
AB	Under provincial consideration		
SK	Under provincial consideration		
MB	Under provincial consideration		
ON	Under provincial consideration		
NS	Funded	Aug 19, 2020	For the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut neuroendocrine tumors (NET's) whose disease has progressed on a somatostatin analogue and is unresectable. Eligible patients include those with progressed SSR+ midgut (defined as jejunioileum and proximal colon in the NETTER-1 trial) NETs with a good performance status. Treatment with 177Lu-Dotatate should be continued until unacceptable toxicity or disease progression, up to a maximum of four infusions with doses given in 8 week intervals. Patients who experience adverse events related to treatment with 177Lu-Dotatate can wait up to 16 weeks between treatments to recover from an adverse event. Patients with SSR+ foregut and hindgut NET's are not eligible for treatment with 177Lu-Dotatate. Retreatment with 177Lu-Dotatate will not be funded.
NB	Not funded		

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NL	Under provincial consideration		
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.